Skip to main content

Table 5 Added predictive value of biomarkers over already known predictors for mean yearly radiographic progression rate over 5 years of treatment

From: The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial

Item

B

95% CI

Standardized beta

P

R 2

Intercept

0.54

0.12 to 0.96

 

0.013

 

Treatment strategy

0.13

-0.16 to 0.43

0.08

0.375

0.000

RF positive

0.29

-0.02 to 0.60

0.15

0.063

0.029

Baseline joint damage

0.09

0.06 to 0.13

0.44

0.000

0.211

EULAR good responsea

-0.36

-0.78 to 0.07

-0.20

0.100

 

EULAR moderate responsea

-0.13

-0.52 to 0.27

-0.07

0.534

0.229

C1,2C change from 1 yr to baseline

-1.11

-1.87 to -0.36

-0.24

0.004

0.283

  1. aEULAR nonresponse was used as reference category. 95% CI, 95% confidence interval; RF, rheumatoid factor.